IMD 0354
Modify Date: 2024-01-08 20:20:22
IMD 0354 structure
|
Common Name | IMD 0354 | ||
|---|---|---|---|---|
| CAS Number | 978-62-1 | Molecular Weight | 383.67300 | |
| Density | 1.561g/cm3 | Boiling Point | 323.1ºC at 760 mmHg | |
| Molecular Formula | C15H8ClF6NO2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 149.2ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of IMD 0354IMD-0354 is a selective IKKβ inhibitor which inhibits NF-κB activity. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC 50 of 1.2±0.3 uM. |
| Name | N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide |
|---|---|
| Synonym | More Synonyms |
| Description | IMD-0354 is a selective IKKβ inhibitor which inhibits NF-κB activity. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC 50 of 1.2±0.3 uM. |
|---|---|
| Related Catalog | |
| Target |
IKKβ NF-κB:1.2 μM (IC50) |
| In Vitro | IMD-0354 inhibits NF-κB activity in HMC-1 cells, resulting in complete repression of growth factor-independent proliferation of mast cells. When the DNA-binding activity of NF-κB is inhibited by treatment with IMD-0354, cell proliferation is completely suppressed. HMC-1 cells are incubated with increasing concentrations of IMD-0354 or STI571 for 24, 48, and 72 hours, and numbers and viability of cells are determined by a dye exclusion test and an MTT assay. IMD-0354 suppresses cell proliferation in a time- and dose-dependent manner. The inhibitory effect of IMD-0354 is remarkable, even at lower concentrations, when compared with that of STI571[1]. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC 50 of 1.2±0.3 uM[2]. |
| In Vivo | Daily administration with 5 mg/kg IMD-0354 significantly suppresses tumor expansion in nude mice implanted with established MDA-MB-231 tumors. In mice treated with IMD-0354, tumor progression is restrained[3]. The number of infiltrating cells in aqueous humor is 53.6±9.8×105, 72.5±17.0×105, 127.25±32.0×105, and 132.0±25.0×105 cells/mL in rats treated with 30, 10, 3, or 0 mg/kg of IMD-0354, respectively. The total protein concentrations of aqueous humor are 92.6±3.1 mg/mL, 101.5±6.8 mg/mL, 112.6±1.9 mg/mL, and 117.33±1.8 mg/mL in rats treated with 30, 10, 3, and 0 mg/kg of IMD-0354, respectively[4]. |
| Cell Assay | HMC-1 cells (2×105 cells/mL) are incubated with various concentrations of IMD-0354 (0.1, 0.5, 1, 5 and 10 uM), STI571, or pyrrolidine dithiocarbamate (PDTC) for the indicated hours, and viable cell numbers are calculated with the use of the trypan blue dye exclusion test at each time point. Cells (2×105 cells/mL) are incubated in phenol red free α-MEM containing 10% FCS (for HMC-1 and IC-2 cells) or 5% FCS (for CBhCMCs), and antibiotics with or without various concentrations of IMD-0354 (0.1, 0.5, 1, 5 and 10 uM), STI571, or PDTC. IC-2WT cells and CBhCMCs are incubated in the presence of 100 ng/mL recombinant rat or recombinant human SCF. One hundred microliters of cell suspension is applied to each well of 96-well culture plates and are incubated for 24, 48, and 72 hours. Before 4 hours from the end of the culture, 10 μL of 5 mg/mL MTT dissolved in PBS is added to each well. The reaction is stopped with the addition of 100 μLof 10% SDS in 0.01 N HCl. Absorbance is measured at 577 nm with ImmunoMini NJ-2300[1]. |
| Animal Admin | Mice[3] MDA-MB-231 cells are suspended in PBS (5×106 cells/100 μL mouse) and s.c. injected to the back of female BALB/c nude mice at the age of 4 to 5 weeks. After growth, the tumor is removed surgically and 100 mg of each established tumor is transplanted to the back of other female nude mice at the age of 4 weeks under ether anesthesia. IMD-0354 is suspended in saline and 5 mg/kg body weight IMD-0354 (suspended in 100 μL/mouse) is given to each mouse by i.p. injection once a day for 28 days after the implantation. Saline is injected in nude mice as a control. Estimated tumor volume (mm3) and tumor weight (mg) are calculated. Rats[4] Eight-week-old male Lewis rats (180-220 g) are used. Endotoxin-induced uveitis (EIU) is induced with subcutaneous injection with 200 μg LPS from Escherichia coli that has been diluted in 200 μL PBS. At the same time, the rats are injected intraperitoneally with 30, 10, or 3 mg/kg of IMD-0354, diluted in 500 μL of 0.5% CMC. Control EIU rats are intraperitoneally administered 500 μL of CMC alone. Naïve rats are used as controls. All experiments are performed in triplicate with five animals in each group. |
| References |
| Density | 1.561g/cm3 |
|---|---|
| Boiling Point | 323.1ºC at 760 mmHg |
| Molecular Formula | C15H8ClF6NO2 |
| Molecular Weight | 383.67300 |
| Flash Point | 149.2ºC |
| Exact Mass | 383.01500 |
| PSA | 49.33000 |
| LogP | 5.40850 |
| Index of Refraction | 1.543 |
| Storage condition | −20°C |
| Water Solubility | Solubility: DMSO (5 mg/ml) or Ethanol (1 mg/ml). |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi |
| Risk Phrases | 36/37/38 |
| Safety Phrases | 26-36 |
| RIDADR | NONH for all modes of transport |
| HS Code | 2924299090 |
|
~87%
IMD 0354 CAS#:978-62-1 |
| Literature: Institute of Medicinal Molecular Design, Inc. Patent: EP1352650 A1, 2003 ; |
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| HS Code | 2924299090 |
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
|
Interleukin 34: a new modulator of human and experimental inflammatory bowel disease.
Clin. Sci. (Lond.) 129 , 281-90, (2015) IBD (inflammatory bowel disease), where CD (Crohn's disease) and UC (ulcerative colitis) represent the two main forms, are chronic inflammatory conditions of the intestine. Macrophages play a central ... |
|
|
TGF-β1 activates the canonical NF-κB signaling to promote cell survival and proliferation in dystrophic muscle fibroblasts in vitro.
Biochem. Biophys. Res. Commun. 471 , 576-81, (2016) Activated fibroblasts continue to proliferate at injury sites, leading to progressive muscular fibrosis in Duchenne muscular dystrophy (DMD). TGF-β1 is a dominant profibrotic mediator thought to play ... |
| IKK-2 Inhibitor V |
| IMD-0354 |